Aprikalim
Alternative Names: RP 52891; RPG 52891Latest Information Update: 08 Jul 2002
At a glance
- Originator Aventis
- Class Anti-ischaemics; Antiasthmatics; Antihypertensives; Ischaemic heart disorder therapies; Vasodilators
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure; Hypertension; Myocardial ischaemia
Most Recent Events
- 22 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 01 Jun 1999 No-Development-Reported for Asthma (PO)
- 10 Jul 1998 No-Development-Reported for Hypertension in Belgium (Unknown route)